Savara Inc
NASDAQ:SVRA
Savara Inc
Long-Term Debt
Savara Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Long-Term Debt
$26.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$60.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$24.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$56.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$112.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
19%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Long-Term Debt?
Long-Term Debt
26.6m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Long-Term Debt amounts to 26.6m USD.
What is Savara Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
1%
Over the last year, the Long-Term Debt growth was 1%. The average annual Long-Term Debt growth rates for Savara Inc have been 7% over the past three years , 1% over the past five years .
You don't have any saved screeners yet